1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Posters by Title

Showing 1,267 results.

Thumbnail for Nationwide Trends in Acute Myeloid Leukemia Mortality Arising From Philadelphia Chromosome-Negative Myeloproliferative Neoplasms in the United States, 1999-2023

AML - 087

Nationwide Trends in Acute Myeloid Leukemia Mortality Arising From Philadelphia Chromosome-Negative Myeloproliferative Neoplasms in the United States, 1999-2023

Valerin Arno Encarnacion

Poster Presenter: Valerin Arno Encarnacion

MM - 548

Navigating Bispecifics Outpatient Step-Up Dosing: A Roadmap to Help Improve Safety and Access in the Real-World (NORTHSTAR)

Muhamed Baljevic

Poster Presenter: Muhamed Baljevic

ABCL - 590

Navigating the WHO-HEAM5 Lymphoma Landscape: An Imaging Primer for Hematologists

Ahmed Salem

Poster Presenter: Ahmed Salem

$Thumbnail for Net Costs Associated With Inpatient Administration of Step-Up Dosing (SUD) of Bispecific Antibodies (bsAbs) Among Medicare Patients With Relapsed/Refractory Multiple Myeloma (MM)$

MM - 768

Net Costs Associated With Inpatient Administration of Step-Up Dosing (SUD) of Bispecific Antibodies (bsAbs) Among Medicare Patients With Relapsed/Refractory Multiple Myeloma (MM)

Timothy Inocencio

Poster Presenter: Timothy Inocencio

CT - 1657

Neurotoxicity across all FDA-approved CAR-T therapies: systematic comparison of pivotal trial and real-world data

GURSHARAN KAUR

Poster Presenter: GURSHARAN KAUR

Thumbnail for Neutrophil-to-Lymphocyte Ratio and SIRI Are Associated with Survival and Relapse in Diffuse Large B-Cell Lymphoma: A Single-Center Study

ABCL - 257

Neutrophil-to-Lymphocyte Ratio and SIRI Are Associated with Survival and Relapse in Diffuse Large B-Cell Lymphoma: A Single-Center Study

Juliana Faleschini

Poster Presenter: Juliana Faleschini

Thumbnail for New IMS/IMWG Consensus Genomic Staging (CGS) Risk Criteria by Next-Generation Sequencing (NGS): Analysis of Daratumumab Benefit in Both High- and Standard-Risk Patients in the PERSEUS/EMN017 Study

MM - 326

New IMS/IMWG Consensus Genomic Staging (CGS) Risk Criteria by Next-Generation Sequencing (NGS): Analysis of Daratumumab Benefit in Both High- and Standard-Risk Patients in the PERSEUS/EMN017 Study

Meletios A Dimopoulos

Poster Presenter: Meletios A Dimopoulos

Video

MM - 1301

NGS Based Assessments of Treatment Response in Patients With Multiple Myeloma Treated With Bispecific T Cell Engagers

Beatriz Mella Soares Pessoa

Poster Presenter: Beatriz Mella Soares Pessoa

Thumbnail for Ninety-Day Readmissions After Hematopoietic Stem Cell Transplantation: A Nationwide Comparative Analysis of Oncologic and Nononcologic Indications

CT - 1087

Ninety-Day Readmissions After Hematopoietic Stem Cell Transplantation: A Nationwide Comparative Analysis of Oncologic and Nononcologic Indications

Ayodeji Johnson

Poster Presenter: Ayodeji Johnson